Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):644–649. doi: 10.1038/bjc.1993.120

The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.

P A Philip 1, L Kaklamanis 1, J Carmichael 1, K Tonkin 1, H Morrison 1, K Gatter 1, A L Harris 1
PMCID: PMC1968348  PMID: 8471420

Abstract

Resistance to cytotoxics precludes the successful treatment of many solid tumours. Inhibition of DNA synthesis in normal tissues with antimetabolites such as hydroxyurea (HU) may be a useful means of improving the selective uptake of toxic thymidine analogues by the relatively resistant tumour cells. HU also inhibits DNA repair by the critical depletion of intracellular deoxyribonucleotides. Twenty-five patients with various malignancies received 5-iodo-2-deoxyuridine (IUdR) 100 mg m-2 as a 20 min i.v. infusion and the uptake of IUdR was determined 1 h later immunocytochemically. Of these patients, 14 received IUdR 23 h from the start of a continuous i.v. infusion of HU (36 g over 36 h). Uptake of IUdR was equally suppressed in bone marrow and tumour aspirates, 0.1% (+/- 0.2%) of marrow precursor cells and 0.5% (+/- 0.4%) of tumour cells respectively, in patients who received HU compared to the uptake of IUdR in 11 patients who were not given HU 6.8% (+/- 1.1%) and 12.2% (+/- 1.8%) respectively. Mean HU plasma concentrations at the time of IUdR administration was 1.7 +/- 0.2 mM. The growth fraction of tumour cells (using Ki67 labelling) was not changed after treatment with HU. It is concluded that (1) since DNA synthesis is effectively inhibited by HU in tumour cells, differential uptake of radiolabelled IUdR by those cells will not be feasible using the current schedule of HU administration, (2) HU may be used as an inhibitor of DNA repair in vivo since the degree of inhibition correlates with that required to inhibit repair experimentally and that (3) Ki67 labelling index is not useful in studying cell kinetics in patients treated with HU.

Full text

PDF
644

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ariel I. M. Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer. 1970 Mar;25(3):705–714. doi: 10.1002/1097-0142(197003)25:3<705::aid-cncr2820250331>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  2. Bagshawe K. D., Boden J., Boxer G. M., Britton D. W., Green A., Partridge T., Pedley B., Sharma S., Southall P. A cytotoxic DNA precursor is taken up selectively by human cancer xenografts. Br J Cancer. 1987 Mar;55(3):299–302. doi: 10.1038/bjc.1987.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bagshawe K. D. Reversed-role chemotherapy for resistant cancer. Lancet. 1986 Oct 4;2(8510):778–781. doi: 10.1016/s0140-6736(86)90301-6. [DOI] [PubMed] [Google Scholar]
  4. Belt R. J., Haas C. D., Kennedy J., Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer. 1980 Aug 1;46(3):455–462. doi: 10.1002/1097-0142(19800801)46:3<455::aid-cncr2820460306>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  5. Bloomer W. D., Adelstein S. J. 5-(125I)-iododeoxyuridine and the Auger effect: biological consequences and implications for therapy. Pathobiol Annu. 1978;8:407–421. [PubMed] [Google Scholar]
  6. CALABRESI P., CARDOSO S. S., FINCH S. C., KLIGERMAN M. M., VON ESSEN C. F., CHU M. Y., WELCH A. D. Initial clinical studies with 5-iodo-2'-deoxyuridine. Cancer Res. 1961 May;21:550–559. [PubMed] [Google Scholar]
  7. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  8. Fabricius E., Rajewsky F. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etud Clin Biol. 1971 Aug-Sep;16(7):679–683. [PubMed] [Google Scholar]
  9. Fornace A. J., Jr, Dobson P. P., Kinsella T. J. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):873–878. doi: 10.1016/0360-3016(90)90410-l. [DOI] [PubMed] [Google Scholar]
  10. Gerdes J. An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer. 1985 Feb 15;35(2):169–171. doi: 10.1002/ijc.2910350205. [DOI] [PubMed] [Google Scholar]
  11. Goldie J. H., Coldman A. J. Genetic instability in the development of drug resistance. Semin Oncol. 1985 Sep;12(3):222–230. [PubMed] [Google Scholar]
  12. Hoshino T., Nagashima T., Murovic J., Levin E. M., Levin V. A., Rupp S. M. Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. Cytometry. 1985 Nov;6(6):627–632. doi: 10.1002/cyto.990060619. [DOI] [PubMed] [Google Scholar]
  13. Kamata T., Yonemura Y., Sugiyama K., Ooyama S., Kosaka T., Yamaguchi A., Miwa K., Miyazaki I. Proliferative activity of early gastric cancer measured by in vitro and in vivo bromodeoxyuridine labeling. Cancer. 1989 Oct 15;64(8):1665–1668. doi: 10.1002/1097-0142(19891015)64:8<1665::aid-cncr2820640818>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Kaung D. T., Walsh W. S., Sbar S., Patno M. E. Hydroxyurea (NSC-32065) in therapy for nonresectable cancer of the lung. Cancer Chemother Rep. 1968 Feb;52(2):271–274. [PubMed] [Google Scholar]
  15. Kinsella T. J., Russo A., Mitchell J. B., Collins J. M., Rowland J., Wright D., Glatstein E. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1941–1946. doi: 10.1016/0360-3016(85)90275-5. [DOI] [PubMed] [Google Scholar]
  16. Lewis W. H., Wright J. A. Altered ribonucleotide reductase activity in mammalian tissue culture cells resistant to hydroxyurea. Biochem Biophys Res Commun. 1974 Oct 8;60(3):926–933. doi: 10.1016/0006-291x(74)90403-3. [DOI] [PubMed] [Google Scholar]
  17. Plagemann P. G., Erbe J. Intracellular conversions of deoxyribonucleosides by Novikoff rat hepatoma cells and effects of hydroxyurea. J Cell Physiol. 1974 Jun;83(3):321–336. doi: 10.1002/jcp.1040830302. [DOI] [PubMed] [Google Scholar]
  18. Sinclair W. K. Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science. 1965 Dec 24;150(3704):1729–1731. doi: 10.1126/science.150.3704.1729. [DOI] [PubMed] [Google Scholar]
  19. Snyder R. D. Inhibitors of ribonucleotide reductase alter DNA repair in human fibroblasts through specific depletion of purine deoxynucleotide triphosphates. Cell Biol Toxicol. 1984 Oct;1(1):81–94. doi: 10.1007/BF00125567. [DOI] [PubMed] [Google Scholar]
  20. Snyder R. D., Van Houten B., Regan J. D. The accumulation of DNA breaks due to incision; comparative studies with various inhibitors. Nucleic Acids Symp Ser. 1984;(13):13–33. [PubMed] [Google Scholar]
  21. Speth P. A., Kinsella T. J., Chang A. E., Klecker R. W., Jr, Belanger K., Smith R., Rowland J., Cupp J. E., Collins J. M. Iododeoxyuridine (IdUrd) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man: as a radiosensitizer and as a marker for cell kinetic studies. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1247–1250. doi: 10.1016/0360-3016(89)90292-7. [DOI] [PubMed] [Google Scholar]
  22. Timson J. Hydroxyurea: comparison of cytotoxic and antimitotic activities against human lymphocytes in vitro. Br J Cancer. 1969 Jun;23(2):337–339. doi: 10.1038/bjc.1969.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Veale D., Cantwell B. M., Kerr N., Upfold A., Harris A. L. Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol. 1988;21(1):53–56. doi: 10.1007/BF00262739. [DOI] [PubMed] [Google Scholar]
  24. Wilson G. D., McNally N. J., Dische S., Saunders M. I., Des Rochers C., Lewis A. A., Bennett M. H. Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer. 1988 Oct;58(4):423–431. doi: 10.1038/bjc.1988.234. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES